Allogene Therapeutics (ALLO) Return on Sales (2021 - 2025)
Historic Return on Sales for Allogene Therapeutics (ALLO) over the last 4 years, with Q4 2024 value amounting to 11510.32%.
- Allogene Therapeutics' Return on Sales fell 77558400.0% to 11510.32% in Q4 2024 from the same period last year, while for Dec 2024 it was 11510.32%, marking a year-over-year decrease of 82531600.0%. This contributed to the annual value of 11708.64% for FY2024, which is 82637400.0% down from last year.
- As of Q4 2024, Allogene Therapeutics' Return on Sales stood at 11510.32%, which was down 77558400.0% from 6384.35% recorded in Q3 2024.
- In the past 5 years, Allogene Therapeutics' Return on Sales ranged from a high of 0.03% in Q4 2021 and a low of 11510.32% during Q4 2024
- Its 4-year average for Return on Sales is 3186.92%, with a median of 2965.59% in 2022.
- As far as peak fluctuations go, Allogene Therapeutics' Return on Sales soared by 4374400bps in 2023, and later tumbled by -77558400bps in 2024.
- Over the past 4 years, Allogene Therapeutics' Return on Sales (Quarter) stood at 0.03% in 2021, then plummeted by -14392819bps to 3601.46% in 2022, then fell by -4bps to 3754.48% in 2023, then tumbled by -207bps to 11510.32% in 2024.
- Its Return on Sales stands at 11510.32% for Q4 2024, versus 6384.35% for Q3 2024 and 4094.6% for Q2 2024.